Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenocarcinoma × regorafenib × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 12 Stomach Neoplasms 3 Neoplasm Metastasis 3 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Tertiary Lymphoid Structures 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdomyosarcoma 1 Mesothelioma, Malignant 1 Melanoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Esophageal Squamous Cell Carcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Gemcitabine 6 pembrolizumab 5 Paclitaxel 4 Capecitabine 4 Nivolumab 3 Fluorouracil 3 Cyclophosphamide 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 sargramostim 2 poly ICLC 2 fludarabine 2 Prednisone 2 Oxaliplatin 2 Irinotecan 2 Dexamethasone 2 Cisplatin 2 130-nm albumin-bound paclitaxel 2 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 rucaparib 1 resiquimod 1 repotrectinib 1 regorafenib 1 pralsetinib 1 olaparib 1 lenvatinib 1 dabrafenib 1 belinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡